Share page on LinkedIn

ICON is a global provider of outsourced development services

ICON has approximately 41,150 employees in 109 locations in 53 countries as at March 31, 2023. In addition to its own global network of offices, ICON can provide service delivery in a total of 93 countries globally, through locally based staff who work from home, and partnerships with local third-party providers. ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology, medical device and government and public health organisations to bring new treatments to market faster. Our services span the entire lifecycle of product development, across a broad range of therapeutic areas, and can be adapted to suit small local trials or large global programs. We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.



ICON services video

Financial figures

  • Full year revenue in 2022 of $7,741.4 million, representing an increase of 41.2% on full year 2021 revenue or 45.4% on a constant currency basis.
  • First quarter 2023 revenue of $1,978.6 million representing an increase of 4.0% on prior year revenue and 5.3% on a constant currency organic basis. 
  • Full year 2023 revenue guidance reaffirmed in the range of $7,940 - $8,340 million, representing a year-on-year increase of 2.6% to 7.7%.

  • Full year 2023 adjusted earnings per share guidance in the range of $12.40 - $13.05, representing a year-on-year increase of 5.5% to 11.1%. 

Q1 2023 financial results

How ICON partners with sponsors and pharma